Atossa Therapeutics Inc

NASDAQ:ATOS   3:59:33 PM EDT
1.02
-0.08 (-6.88%)
Products

Atossa Therapeutics Says On June 1, Submitted An Investigational New Drug To FDA For Atossa's Proprietary Oral (Z)-Endoxifen Capsules

Published: 06/06/2022 18:54 GMT
Atossa Therapeutics Inc (ATOS) - Atossa Therapeutics - on June 1, Submitted an Investigational New Drug to FDA for Atossa's Proprietary Oral (z)-endoxifen Capsules.
Atossa Therapeutics - Initial Investigation Will Be a Phase 2 Study of Premenopausal Women With Er+/her2- Breast Cancer.
Further Company Coverage: Atoso ((reuters.
Briefs@thomsonreuters.
Com;)).